Key result
Implantable cardioverter/defibrillator therapy should be considered in patients at high risk for recurrent syncope due to fatal ventricular arrhythmias triggered by coronary spasm.
In patients with vasospastic angina and unexplained syncope, prompt diagnosis and consideration of ICD therapy are crucial to avert sudden cardiac death from lethal arrhythmias.
Supports ICD consideration in high-risk coronary spasm syncope; leaves open prospective trials to confirm benefit.
The coronary artery diseases (CAD) that can lead to the occurrence of a syncopal attack include acute coronary syndrome, vasospastic angina, effort angina, and prior myocardial infarction. The possible mechanisms considered to lead to syncope in patients with CAD are pump failure, tachyarrhythmia, bradycardia, and vagal stimulation. Coronary artery spasm, in particular, is occasionally observed in patients with unexplained syncope in Japan. Life-threatening arrhythmias are among the most serious complications of an ischemic attack caused by coronary spasm, and are associated with an increased risk of syncope and/or sudden cardiac death (SCD). Therefore, during the initial evaluation of unexplained syncope, the diagnosis of vasospastic angina (VSA) needs to be made promptly, to avert the risk of SCD as a consequence of syncope triggered by the lethal arrhythmia. The inducibility of polymorphic ventricular tachycardia or ventricular fibrillation, increased QT dispersion, T-wave alternans, and early repolarization during the asymptomatic period are considered risk markers for ventricular arrhythmias during coronary spasm. In view of the conclusions from several studies, implantable cardioverter/defibrillator therapy should be considered in patients who are at high risk for recurrence of syncope due to a fatal ventricular arrhythmia triggered by coronary spasm, despite appropriate medical therapy.
No takes yet. Share an insight, caveat, or question.
Mitsuhiro Nishizaki (2017) conducted a review in Vasospastic angina with syncope. Implantable cardioverter/defibrillator therapy was evaluated. Implantable cardioverter/defibrillator therapy should be considered in patients at high risk for recurrent syncope due to fatal ventricular arrhythmias triggered by coronary spasm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: